Ph2 study of AAA817 in participants with Lu-PSMA radiolgand therapy
Phase II/III Clinical Trial
PSMAcTION: A phase II/III open-label international multicenter randomized study of AAA817 versus standard of care in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA targeted therapyProtocol No.: CAAA817A12201